The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC).
Robert L. Ferris
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Amgen; Bristol-Myers Squibb
Nicole Cherie Schmitt
No relevant relationships to disclose
Dwight Earl Heron
No relevant relationships to disclose
Jonas Talmadge Johnson
No relevant relationships to disclose
Seungwon Kim
No relevant relationships to disclose
Umamaheswar Duvvuri
Honoraria - Novartis
David Andrew Clump
No relevant relationships to disclose
Jennifer Grandis
Research Funding - Bristol-Myers Squibb; Novartis
Julie E. Bauman
Research Funding - Bristol-Myers Squibb; Genentech; Lilly
William E. Gooding
No relevant relationships to disclose
Athanassios Argiris
No relevant relationships to disclose